New cell therapy targets lingering lymphoma
NCT ID NCT07006012
First seen Apr 16, 2026 · Last updated Jun 10, 2026 · Updated 9 times
Summary
This early study tests a new cell therapy called RGL-305 in 12 adults with lymphoma who still have signs of disease after standard treatment. The goal is to see if it is safe and how it works in the body. Researchers will monitor side effects and check if the therapy can reduce remaining cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA PATIENTS WITH COMPLETE RESPONSE (CR) OR PARTIAL RESPONSE (PR) AFTER STANDARD TREATMENT HAD A POSITIVE MINIMAL RESIDUAL LESION (MRD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.